Comparison of imipenem and ceftazidime as therapy for severe melioidosis

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 381-387

  Simpson, Andrew J H ^a,b,c,d   Suputtamongkol, Yupin ^a,b,c,d,e   Smith, Michael D ^a,b,c,d,f   Angus, Brian J ^a,b,c,d   Rajanuwong, Adul ^a,b,c,d   Wuthiekanun, Vanaporn ^a,b,c,d   Howe, Paul A ^a,b,c,d   Walsh, Amanda L ^a,b,c,d,g   Chaowagul, Wipada ^a,b,c,d   White, Nicholas J ^a,b,c,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Sappasitthiprasong Hospital   (Thailand)

^c Centre for Tropical Medicine   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e MAHIDOL UNIVERSITY   (Thailand)

^f MUSGROVE PARK HOSPITAL   (United Kingdom)

^g Malaria Proj/Wellcome Trust Res L   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM;

ADULT; ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CLINICAL TRIAL; CONVULSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELIOIDOSIS; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

EID: 0032777243     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520219     Document Type: Article

References (17)

1. 1. Leelarasamee A, Bovornkitti S. Melioidosis: review and update. Rev Infect Dis 1989;11:413-25.
2. 2. White NJ, Dance DAB, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989;ii:697-701.
3. 3. Sookprance M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and cotrimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992;36:158-62.
4. 4. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994;19:846-53.
5. 5. Thamprajamchit S, Chetchotisakd P, Thinkhamrop B. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. J Med Assoc Thai 1998;81:265-71.
6. 6. Dance DAB, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 1989;24: 295-309.
7. 7. Lumbiganon P, Saengsa-Ard S, Wilailuckana C. Imipenem therapy for melioidosis in two children. Pediatr Infect Dis J 1992;11:414-6.
8. 8. Suputtamongkol Y, Hall AJ, Dance DAB, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol 1994;23:1082-90.
9. 9. Walsh AL, Smith MD, Wuthiekanun V, et al. Prognostic significance of quantitative bacteremia in septicemic melioidosis. Clin Infect Dis 1995; 21:1498-1500.
10. 10. Walsh AL, Wuthiekanun V. The laboratory diagnosis of melioidosis. Br J Biomed Sci 1996;53:249-53.
11. 11. Walsh AL, Smith MD, Wuthiekanun V, et al. Immunofluorescence microscopy for the rapid diagnosis of melioidosis. J Clin Pathol 1994;47: 377-9.
12. 12. Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991;27(suppl D):1-50.
13. 13. Dance DAB. Melioidosis: the tip of the iceberg? Clin Microbiol Rev 1991;4:52-60.
14. 14. Chaowagul W, White NJ, Dance DAB, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989;159:890-9.
15. 15. Smith MD, Wuthiekanun V, Walsh AL, White NJ. In-vitro activity of carbapenem antibiotics against β-lactam susceptible and resistant strains of Burkholderia pseudomalleri. J Antimicrob Chemother 1996;37:611-5.
16. 16. Smith MD, Wuthiekanun V, Walsh AL, White NJ. Susceptibility of Pseudomonas pseudomallei to some newer β-lactam antibiotics and antibiotic combinations using time-kill studies. J Antimicrob Chemother 1994;33:145-9.
17. 17. Prins JM, van Deventer SJH, Kuiper EJ, Speelman P. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 1994;38:1211-8.